mBC Treatment Discussions at ASCO 2026
One of the most discussed themes at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was how treatment decisions are evolving for people living with metastatic breast cancer.
Researchers are increasingly focused not only on which treatments work, but also on when they should be used. Advances in precision medicine, blood-based monitoring, and targeted therapies are helping clinicians make more informed decisions throughout a patient’s care journey. The goal is to delay disease progression, extend the benefit of treatment, and support patients in maintaining their quality of life.
ASCENT-04: Looking at Treatment Earlier
The ASCENT-04 trial reflects growing interest in using some of the most effective therapies earlier in treatment for patients with metastatic triple-negative breast cancer (mTNBC). Building on previous research involving sacituzumab govitecan, investigators are studying whether introducing these treatments sooner can extend disease control and increase the time patients benefit from therapy.
The study reflects a broader shift in metastatic breast cancer care. Rather than simply moving from one treatment to another when cancer progresses, researchers are exploring whether treatment sequencing can help maintain disease stability and preserve future treatment options. As more treatment options become available, understanding when to use them is becoming just as important as understanding how they work.
SERENA-6 and Earlier Action
Another important study generating discussion at ASCO 2026 was SERENA-6, which explored whether treatment changes should happen before cancer growth appears on scans.
Using a simple blood test, researchers can detect changes in tumor DNA that may signal a treatment is becoming less effective. In some cases, these changes can be identified months before progression is visible through imaging. This approach could allow clinicians to act earlier, adjusting treatment based on molecular changes rather than waiting for visible disease progression.
FOR patients, this may one day allow treatment decisions to be made earlier, helping reduce the impact of progression before it becomes clinically apparent.
Residual Disease and Preventing Metastatic Breast Cancer
While much of the discussion at ASCO focused on treating metastatic breast cancer, researchers are also working to identify patients at higher risk of developing metastatic disease in the future.
One key area of focus is residual disease—cancer that remains after initial treatment. For some patients with early-stage breast cancer, residual disease can indicate a higher risk of recurrence and future metastasis.
Research presented at ASCO 2026 continues to explore how treatment response can be used to guide more personalized care. By identifying individuals at higher risk earlier, clinicians may be able to tailor treatment strategies aimed at reducing the likelihood of recurrence and helping prevent metastatic disease from developing.
Canadian breast cancer expert Dr. David Cescon, Medical Oncologist and Clinician Scientist at Princess Margaret Cancer Centre, has contributed to research in this area, advancing the understanding of treatment response and risk assessment. His work reflects a broader shift toward personalized care, where treatment decisions are increasingly guided by the biology of each patient’s cancer and how it responds to therapy.
Understanding PFS2
As treatment options continue to expand, researchers are also looking at new ways to measure success. One measure receiving growing attention is PFS2, or progression-free survival 2.
In simple terms, PFS2 looks beyond the first treatment and asks a broader question: How does the order of treatment impact longer cancer control? Rather than focusing on a single therapy, PFS2 measures how patients do across the first treatment and then the next treatment over time. This provides a more complete picture of how today’s treatment decisions may influence long-term outcomes. For people living with metastatic breast cancer, this reflects the reality that care often involves a series of treatments delivered over many years.
What This Means for Patients
Together, the studies presented at ASCO 2026 highlight a growing shift toward more personalized breast cancer care.
- For people living with metastatic breast cancer: Researchers are working to better understand how treatment sequencing, blood-based monitoring, and emerging therapies can help maintain disease control and extend the benefit of available treatments.
- For early-stage patients: Advances in understanding residual disease may help identify individuals at higher risk of recurrence, creating opportunities for earlier intervention and more individualized treatment approaches.
The common goal is clear: to deliver the right treatment at the right time, preserve future treatment options, reduce the risk of recurrence where possible, optimize the order of treatment for longer cancer control, and support patients in living well while managing breast cancer. As researchers continue to refine how therapies are selected, sequenced, and monitored, these advances are moving the field closer to a future where treatment decisions are increasingly tailored to the unique characteristics of each patient’s disease.
References
- ASCENT-04 Trial
Bardia A, et al. ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab in previously untreated PD-L1–positive metastatic triple-negative breast cancer.
ASCO Annual Meeting Abstract LBA109
https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA109 - SERENA-6 Trial
Turner NC, et al. ctDNA-guided treatment switching with camizestrant in HR-positive, HER2-negative advanced breast cancer.
ASCO Annual Meeting Abstract LBA4
https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA4 - Understanding PFS2
Progression-free survival 2 (PFS2) as a clinical trial endpoint in oncology research.
Journal of Clinical Oncology
https://ascopubs.org/doi/10.1200/JCO.22.01533 - Residual Disease and Breast Cancer Recurrence Risk
Concepts in residual disease following neoadjuvant therapy and implications for recurrence risk and treatment planning.
ASCO Educational Book
https://ascopubs.org/doi/10.1200/EDBK_520754
